Fractionated administration of irinotecan and cisplatin for treatment of non-small-cell lung cancer: A phase II study of Okayama Lung Cancer Study Group

H. Ueoka, M. Tanimoto, K. Kiura, M. Tabata, N. Takigawa, Y. Segawa, I. Takata, K. Eguchi, N. Okimoto, S. Harita, H. Kamei, T. Shibayama, Y. Watanabe, S. Hiraki, M. Harada

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

A phase II study of fractionated administration of irinotecan (CPT-11) and cisplatin (CDDP) in patients with non-small-cell lung cancer (NSCLC) was conducted. Between January 1996 and January 1998, 44 previously untreated patients with stage IIIB or IV NSCLC were enrolled. CDDP at a dose of 60 mg m -2 was given first and followed by CPT-11 at a dose of 50 mg m -2. Both drugs were given by 1 -hour infusion on days 1 and 8, and repeated every 4 weeks up to 4 cycles, 42 patients were evaluated for response and 44 for survival and toxicity. 20 patients (48%: 95% confidence interval 32-63%) achieved an objective response. The median duration of responses was 8 months, and the median survival time and the 1-year survival rate were 12.5 months and 56.8%, respectively. Major toxicities were neutropenia and diarrhoea. Grade 3 or 4 neutropenia occurred in 70.5% of the patients and one patient died of sepsis. Grade 3 or 4 diarrhoea was experienced in 25.0%, but manageable by conventional therapy. In conclusion, fractionated administration of CPT-11 and CDDP was highly effective for advanced NSCLC with manageable toxicities.

Original languageEnglish
Pages (from-to)9-13
Number of pages5
JournalBritish Journal of Cancer
Volume85
Issue number1
DOIs
Publication statusPublished - Jul 6 2001

Keywords

  • Cisplatin
  • Fractionated administration
  • Irinotecan
  • Non-small-cell lung cancer
  • Phase II study

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Fractionated administration of irinotecan and cisplatin for treatment of non-small-cell lung cancer: A phase II study of Okayama Lung Cancer Study Group'. Together they form a unique fingerprint.

  • Cite this

    Ueoka, H., Tanimoto, M., Kiura, K., Tabata, M., Takigawa, N., Segawa, Y., Takata, I., Eguchi, K., Okimoto, N., Harita, S., Kamei, H., Shibayama, T., Watanabe, Y., Hiraki, S., & Harada, M. (2001). Fractionated administration of irinotecan and cisplatin for treatment of non-small-cell lung cancer: A phase II study of Okayama Lung Cancer Study Group. British Journal of Cancer, 85(1), 9-13. https://doi.org/10.1054/bjoc.2001.1861